Abstract Body

Background

Reports of HIV acquisition among persons on cabotegravir (CAB) PrEP are rare thus far in routine clinical care but have occurred. We report the largest analysis to date of diagnostics, pharmacokinetics, resistance, provider-selected ART and treatment outcomes following HIV acquisition on CAB PrEP in routine care.

Methods

The SeroPrEP study examines HIV acquisition on PrEP in routine care in the U.S. Clinical test results (including HIV RNA) were obtained from medical records. HIV RNA was also quantified by automated single-copy assay. Resistance-associated mutations (RAMs) in plasma HIV RNA were identified by single-genome sequencing (SGS) of full-length integrase. Plasma CAB concentrations were quantified by LC/MS/MS.

Results

Among 7 participants (ppts; 6 cisgender male, 1 nonbinary) diagnosed with HIV after CAB PrEP use, median age was 38 years (range 23-67), median BMI 27 kg/m2 (range 18-36). HIV was first detected in 6 ppts after median 7 (range 2-13) on-time injections and in 1 ppt 9 mos. after last injection. At first HIV detection, HIV RNA was <500 c/ml in 3/7 (43%) ppts; median HIV RNA 4410 c/ml (range 100-2,400,000); Ag/Ab (lab-based or POC) was reactive in 3/7 (43%). Plasma CAB levels measured median 49 days (range 14-102) after last injection were median 0.99 mcg/ml (range 0.24-3.4). One ppt had major INSTI RAMs (E138EK/Q148QK/N155NH) on population sequencing. Among 4/6 other ppts, SGS identified low-frequency major INSTI RAMs: N=1 ppt with Q148R (2/24 sequences [seq]); N=1 with E138K (1/56 seq)/G140R (1/41 seq); N=1 with Q148R (12/40 seq)/R263K (1/40 seq)/G118R (2/15 seq); N=1 with S147G (1/45 seq). All 7 ppts started DRV-based ART; among 6 on ART >6 wks, all had HIV RNA <50 c/ml through median 28 wks (range 7-74). Three ppts with low-frequency INSTI RAMs later switched to provider-selected INSTI-based ART due to ARV intolerance/interactions or pt preference, with subsequent HIV RNA <50 c/ml at 31 wks (BIC/F/TAF), 20 wks (BIC/F/TAF to CAB/RPV), and 13 wks (CAB/RPV).

Conclusions

Among 7 persons in the U.S. who acquired HIV despite CAB PrEP use, over half required RNA for initial HIV detection and had low-frequency INSTI RAMs detected by a sensitive assay. All started DRV-based ART (3 later switched to INSTI-based ART) and all achieved viral suppression to date. Longer-term follow-up is needed to assess the clinical significance of low-frequency INSTI RAMs detected by sensitive assays, and the durability of viral suppression on INSTI-based ART after HIV infection on CAB PrEP.